NovaBay Pharmaceuticals, Inc. (NBY)
USD 0.49
(-0.45%)
USD 0.49
(-0.45%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -138.65 USD | 77.33% |
| 2022 | -353.59 USD | -92.02% |
| 2021 | -184.09 USD | 52.27% |
| 2020 | -385.53 USD | 35.02% |
| 2019 | -593.63 USD | -25.26% |
| 2018 | -473.83 USD | 19.93% |
| 2017 | -591.81 USD | 65.49% |
| 2016 | - USD | 79.47% |
| 2015 | - USD | 10.9% |
| 2014 | - USD | 27.17% |
| 2013 | - USD | -75.16% |
| 2012 | -208.80 USD | -21.65% |
| 2011 | -172.64 USD | -6.83% |
| 2010 | -161.60 USD | -253.9% |
| 2009 | 105.00 USD | 131.52% |
| 2008 | -333.14 USD | 36.73% |
| 2007 | -526.52 USD | 34.95% |
| 2006 | -809.37 USD | -29.6% |
| 2005 | -624.53 USD | -11.43% |
| 2004 | -560.46 USD | -165.08% |
| 2003 | -211.43 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.13 USD | 89.43% |
| 2024 Q2 | -1.37 USD | 72.15% |
| 2023 Q1 | -0.85 USD | 80.37% |
| 2023 FY | - USD | 77.33% |
| 2023 Q2 | -1.27 USD | -49.41% |
| 2023 Q3 | -0.37 USD | 70.87% |
| 2023 Q4 | -0.37 USD | 0.0% |
| 2022 Q4 | -4.33 USD | -19.94% |
| 2022 Q1 | -0.08 USD | 88.75% |
| 2022 FY | - USD | -92.02% |
| 2022 Q2 | -1.43 USD | -1742.78% |
| 2022 Q3 | -3.61 USD | -152.45% |
| 2021 Q4 | -0.69 USD | 61.24% |
| 2021 FY | - USD | 52.27% |
| 2021 Q1 | -1.27 USD | 13.61% |
| 2021 Q2 | -1.53 USD | -20.47% |
| 2021 Q3 | -1.78 USD | -16.34% |
| 2020 Q4 | -1.47 USD | 47.87% |
| 2020 Q1 | -1.98 USD | 55.2% |
| 2020 Q2 | -5.16 USD | -160.61% |
| 2020 FY | - USD | 35.02% |
| 2020 Q3 | -2.82 USD | 45.35% |
| 2019 Q2 | -4.76 USD | 44.52% |
| 2019 Q4 | -4.42 USD | -718.52% |
| 2019 FY | - USD | -25.26% |
| 2019 Q1 | -8.58 USD | -230.0% |
| 2019 Q3 | -0.54 USD | 88.66% |
| 2018 Q2 | -3.25 USD | 29.19% |
| 2018 FY | - USD | 19.93% |
| 2018 Q3 | -3.15 USD | 3.08% |
| 2018 Q4 | -2.60 USD | 17.46% |
| 2018 Q1 | -4.59 USD | -371.6% |
| 2017 Q3 | -5.60 USD | -41.06% |
| 2017 Q2 | -3.97 USD | 56.8% |
| 2017 Q1 | -9.19 USD | -143.12% |
| 2017 FY | - USD | 65.49% |
| 2017 Q4 | 1.69 USD | 130.18% |
| 2016 Q1 | -43.49 USD | -20.77% |
| 2016 Q4 | -3.78 USD | 68.45% |
| 2016 FY | - USD | 79.47% |
| 2016 Q3 | -11.98 USD | 5.74% |
| 2016 Q2 | -12.71 USD | 70.77% |
| 2015 Q2 | -64.47 USD | 13.66% |
| 2015 Q4 | -36.01 USD | 41.96% |
| 2015 Q3 | -62.04 USD | 3.77% |
| 2015 FY | - USD | 10.9% |
| 2015 Q1 | -74.67 USD | -3.85% |
| 2014 Q4 | -71.90 USD | 1.02% |
| 2014 Q1 | -70.00 USD | 12.32% |
| 2014 FY | - USD | 27.17% |
| 2014 Q2 | -52.50 USD | 25.0% |
| 2014 Q3 | -72.64 USD | -38.36% |
| 2013 Q4 | -79.84 USD | 11.16% |
| 2013 Q2 | -96.25 USD | 0.0% |
| 2013 Q3 | -89.87 USD | 6.63% |
| 2013 FY | - USD | -75.16% |
| 2013 Q1 | -96.25 USD | -72.06% |
| 2012 Q4 | -55.94 USD | -2402.06% |
| 2012 FY | - USD | -21.65% |
| 2012 Q1 | -77.51 USD | 31.07% |
| 2012 Q2 | -67.94 USD | 12.35% |
| 2012 Q3 | 2.43 USD | 103.58% |
| 2011 Q4 | -112.44 USD | -3486.75% |
| 2011 Q2 | 17.50 USD | 123.57% |
| 2011 Q1 | -74.25 USD | -1335.44% |
| 2011 FY | - USD | -6.83% |
| 2011 Q3 | 3.32 USD | -81.03% |
| 2010 Q3 | -61.57 USD | -36.94% |
| 2010 Q4 | 6.01 USD | 109.76% |
| 2010 Q2 | -44.96 USD | 26.51% |
| 2010 Q1 | -61.18 USD | -147.6% |
| 2010 FY | - USD | -253.9% |
| 2009 Q3 | -4.18 USD | 63.75% |
| 2009 Q2 | -11.53 USD | 10.41% |
| 2009 Q1 | -12.87 USD | 79.59% |
| 2009 FY | - USD | 131.52% |
| 2009 Q4 | 128.52 USD | 3174.64% |
| 2008 Q1 | -110.07 USD | -91.93% |
| 2008 Q4 | -63.07 USD | -3.8% |
| 2008 Q3 | -60.76 USD | 38.53% |
| 2008 FY | - USD | 36.73% |
| 2008 Q2 | -98.85 USD | 10.19% |
| 2007 Q2 | -209.61 USD | -72.11% |
| 2007 Q1 | -121.79 USD | -28.08% |
| 2007 Q3 | -207.44 USD | 1.04% |
| 2007 Q4 | -57.35 USD | 72.35% |
| 2007 FY | - USD | 34.95% |
| 2006 Q3 | -108.80 USD | 57.0% |
| 2006 FY | - USD | -29.6% |
| 2006 Q2 | -253.05 USD | -140.59% |
| 2006 Q1 | -105.18 USD | 32.65% |
| 2006 Q4 | -95.09 USD | 12.6% |
| 2005 Q4 | -156.18 USD | 0.0% |
| 2005 Q2 | -156.18 USD | 0.0% |
| 2005 FY | - USD | -11.43% |
| 2005 Q3 | -156.18 USD | 0.0% |
| 2005 Q1 | -156.18 USD | 0.0% |
| 2004 FY | - USD | -165.08% |
| 2003 FY | - USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -0.60 USD | -23008.333% |
| Ampio Pharmaceuticals, Inc. | -10.67 USD | -1199.438% |
| Armata Pharmaceuticals, Inc. | -1.91 USD | -7159.162% |
| Actinium Pharmaceuticals, Inc. | -1.83 USD | -7476.503% |
| Azitra, Inc. | -54.76 USD | -153.196% |
| Can-Fite BioPharma Ltd. | -1.79 USD | -7645.81% |
| Chromocell Therapeutics Corporation | -1.28 USD | -10732.031% |
| Calidi Biotherapeutics, Inc. | -1.73 USD | -7914.451% |
| CEL-SCI Corporation | -0.73 USD | -18893.151% |
| iBio, Inc. | -6.50 USD | -2033.077% |
| Lineage Cell Therapeutics, Inc. | -0.12 USD | -115441.667% |
| MAIA Biotechnology, Inc. | -1.49 USD | -9205.369% |
| Matinas BioPharma Holdings, Inc. | -5.28 USD | -2525.947% |
| Navidea Biopharmaceuticals, Inc. | -0.59 USD | -23400.0% |
| NanoViricides, Inc. | -0.70 USD | -19707.143% |
| Oragenics, Inc. | -9.18 USD | -1410.349% |
| BiomX Inc. | -5.10 USD | -2618.627% |
| BiomX Inc. | -5.10 USD | -2618.627% |
| Protalix BioTherapeutics, Inc. | 0.12 USD | 115641.667% |
| Palatin Technologies, Inc. | -2.02 USD | -6763.861% |
| Scorpius Holdings, Inc. | -347.20 USD | 60.066% |
| Theriva Biologics, Inc. | -28.49 USD | -386.662% |